307 related articles for article (PubMed ID: 28524179)
1. A FKBP5 mutation is associated with Paget's disease of bone and enhances osteoclastogenesis.
Lu B; Jiao Y; Wang Y; Dong J; Wei M; Cui B; Sun Y; Wang L; Zhang B; Chen Z; Zhao Y
Exp Mol Med; 2017 May; 49(5):e336. PubMed ID: 28524179
[TBL] [Abstract][Full Text] [Related]
2. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment.
Hiruma Y; Kurihara N; Subler MA; Zhou H; Boykin CS; Zhang H; Ishizuka S; Dempster DW; Roodman GD; Windle JJ
Hum Mol Genet; 2008 Dec; 17(23):3708-19. PubMed ID: 18765443
[TBL] [Abstract][Full Text] [Related]
3. p62 ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-kappaB ligand-induced osteoclast formation: a new insight into the pathogenesis of Paget's disease of bone.
Yip KH; Feng H; Pavlos NJ; Zheng MH; Xu J
Am J Pathol; 2006 Aug; 169(2):503-14. PubMed ID: 16877352
[TBL] [Abstract][Full Text] [Related]
4. Effect of a rare genetic variant of TM7SF4 gene on osteoclasts of patients with Paget's disease of bone.
Laurier E; Amiable N; Gagnon E; Brown JP; Michou L
BMC Med Genet; 2017 Nov; 18(1):133. PubMed ID: 29145829
[TBL] [Abstract][Full Text] [Related]
5. p62/sequestosome 1 deficiency accelerates osteoclastogenesis
Zach F; Polzer F; Mueller A; Gessner A
J Biol Chem; 2018 Jun; 293(24):9530-9541. PubMed ID: 29555685
[TBL] [Abstract][Full Text] [Related]
6. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
7. 9-Hydroxy-6,7-dimethoxydalbergiquinol inhibits osteoclast differentiation through down-regulation of Akt, c-Fos and NFATc1.
Kim JY; Kim JY; Cheon YH; Kwak SC; Baek JM; Kim YC; Yoon KH; Oh J; Lee MS
Int Immunopharmacol; 2014 May; 20(1):213-20. PubMed ID: 24630975
[TBL] [Abstract][Full Text] [Related]
8. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
9. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
[TBL] [Abstract][Full Text] [Related]
10. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype.
Rea SL; Walsh JP; Ward L; Yip K; Ward BK; Kent GN; Steer JH; Xu J; Ratajczak T
J Bone Miner Res; 2006 Jul; 21(7):1136-45. PubMed ID: 16813535
[TBL] [Abstract][Full Text] [Related]
11. Osteoclast signaling-targeting miR-146a-3p and miR-155-5p are downregulated in Paget's disease of bone.
Stephens E; Roy M; Bisson M; Nguyen HD; Scott MS; Boire G; Bouchard L; Roux S
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165852. PubMed ID: 32485219
[TBL] [Abstract][Full Text] [Related]
12. A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice.
Daroszewska A; van 't Hof RJ; Rojas JA; Layfield R; Landao-Basonga E; Rose L; Rose K; Ralston SH
Hum Mol Genet; 2011 Jul; 20(14):2734-44. PubMed ID: 21515589
[TBL] [Abstract][Full Text] [Related]
13. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade.
Moon JB; Kim JH; Kim K; Youn BU; Ko A; Lee SY; Kim N
J Immunol; 2012 Jan; 188(1):163-9. PubMed ID: 22131333
[TBL] [Abstract][Full Text] [Related]
14. Docosahexaenoic acid signaling attenuates the proliferation and differentiation of bone marrow-derived osteoclast precursors and promotes apoptosis in mature osteoclasts.
Kim HJ; Ohk B; Yoon HJ; Kang WY; Seong SJ; Kim SY; Yoon YR
Cell Signal; 2017 Jan; 29():226-232. PubMed ID: 27836739
[TBL] [Abstract][Full Text] [Related]
15. Purslane suppresses osteoclast differentiation and bone resorbing activity via inhibition of Akt/GSK3β-c-Fos-NFATc1 signaling in vitro and prevents lipopolysaccharide-induced bone loss in vivo.
Kim JY; Oh HM; Kwak SC; Cheon YH; Lee MS; Rho MC; Oh J
Biol Pharm Bull; 2015; 38(1):66-74. PubMed ID: 25744460
[TBL] [Abstract][Full Text] [Related]
16. ATF3 modulates calcium signaling in osteoclast differentiation and activity by associating with c-Fos and NFATc1 proteins.
Jeong BC; Kim JH; Kim K; Kim I; Seong S; Kim N
Bone; 2017 Feb; 95():33-40. PubMed ID: 27829167
[TBL] [Abstract][Full Text] [Related]
17. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
18. WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
Cheon YH; Kim JY; Baek JM; Ahn SJ; Jun HY; Erkhembaatar M; Kim MS; Lee MS; Oh J
J Bone Miner Res; 2016 Feb; 31(2):403-15. PubMed ID: 26255791
[TBL] [Abstract][Full Text] [Related]
19. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
20. NFAM1 signaling enhances osteoclast formation and bone resorption activity in Paget's disease of bone.
Sambandam Y; Sundaram K; Saigusa T; Balasubramanian S; Reddy SV
Bone; 2017 Aug; 101():236-244. PubMed ID: 28506889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
